疫苗契约製造市场（按疫苗类型、技术平台、服务提供、应用类型、使用阶段和最终用户划分）—2025-2032 年全球预测

预计到 2032 年，疫苗契约製造市场将成长至 114.3 亿美元，复合年增长率为 9.53%。

主要市场统计数据
基准年2024年	55.1亿美元
预计2025年	60.4亿美元
预测年份：2032年	114.3亿美元
复合年增长率（%）	9.53%

策略方向将疫苗契约製造定位为塑造公共卫生成果、商业化速度和跨境韧性的关键能力

疫苗契约製造领域正从单一的供应解决方案演变为涵盖全球公共卫生、商业性药物开发和地缘政治韧性的策略轴心。製造商、开发商和政策领导者越来越多地将製造外包视为一种可配置的能力，它可以决定专案时间表、监管风险和患者可及性。因此，决策者需要一种整合的观点，将技术能力与製剂、填充、分析表征和物流环节的服务编配连结起来。

本导言强调了技术进步、监管预期和地缘政治压力如何共同创造风险和机会，为建构综合观点铺平了道路。它概述了影响合作伙伴选择和能力投资的关键因素：疫苗模式多样性、平台复杂性、服务范围、临床和商业阶段要求以及最终用户优先顺序。将营运能力与策略成果挂钩有助于经营团队确定近期行动的优先顺序（例如，确保双源供应链或加速一次性系统的检验）。从认知到结构化决策的转变需要清楚地了解科学、监管和物流之间的相互作用。

技术创新、监管敏捷性和综合服务模式如何重新定义疫苗受託製造的竞争优势

过去五年，製造业和研究服务的采购方式发生了翻天覆地的变化。 mRNA 和病毒载体平台架构的进步、模组化和一次性设施架构的日益普及，以及细胞技术和非细胞技术的兴起，拓展了可行的专案设计范围。这些技术变革也带来了营运方面的进步：更复杂的分析技术正在缩短开发週期，灌装-完成自动化正在降低差异性并加快规模化生产。

同时，监管机构正在采取更具适应性的审查路径，并展现出依赖真实世界数据来支持核准后监测的意愿。这些监管变革正推动申办方和製造商共同製定基于特定场地、数据主导的验证策略。市场参与企业正透过建立更深层、以能力主导的伙伴关係（而非一次性交易安排）来应对这项挑战。因此，受託製造製造商正在上游工程拓展，涵盖原料药药营运、製剂开发和整合分析等领域，成为全生命週期合作伙伴。总而言之，这些转变创造了一个全新的竞争环境，其中技术敏捷性、监管熟悉度和服务整合决定了竞争优势和专案韧性。

评估美国近期关税变化如何改变疫苗生产的筹资策略、供应商合格和区域投资决策

美国新的贸易政策和关税方案带来了新的成本和营运考量，并波及全球供应链。关税相关的摩擦正在推高进口原材料、一次性零件和专用器械的总到岸成本，促使申办方和製造商重新评估筹资策略。为此，医疗保健机构正在多元化其供应商基础，寻找关键投入的本地替代方案，并加快库存规划以确保专案的连续性。

关税也影响资本投资位置决策。投资者和策略团队正在权衡近岸和在岸产能的韧性与现有离岸产能的固定成本优势。这种考量促使人们开始关注建立区域枢纽，以降低跨境贸易政策波动带来的风险，同时保持对熟练劳动力资源的取得和对监管的熟悉。同时，契约製造製造商正在提高供应链透明度，并投资于采购能力，以减轻关税的影响。此类营运响应措施降低了专案突然中断的可能性，使专案发起方能够尽可能采用多模态物流和在地采购策略来确保专案按时完成。

深度细分主导的洞察，将疫苗模式、平台架构、服务产品、应用阶段和最终用户行为映射到伙伴关係和投资选择

细緻的细分视角能够清楚揭示策略价值所在以及能力差距所在。在分析疫苗多样性（DNA疫苗、灭活疫苗、减毒疫苗、mRNA疫苗、类毒素疫苗、病毒载体疫苗）时，每种疫苗的上下游加工需求和监管环节均有所不同，这要求各组织将技术需求与生产专业知识结合。细胞培养方法分为贴壁细胞培养和悬浮细胞培养，而无细胞、卵子和合成胜肽平台则面临独特的规模化生产和分析挑战。

分析服务、原料药 (API) 製造、填充和封口、配方服务、分销和包装各自都需要独特的能力和品质系统。预防性疫苗和治疗性疫苗应用之间的差异会影响批次放行策略、滴度测定和上市后研究途径。临床阶段专案需要灵活的製造和快速的变更管理，涵盖 I、II 和 III 期研究；而商业阶段专案则需要高效的能力、可持续的供应协议和成熟的品管系统。最后，最终用户类别（生物技术公司、政府机构和製药公司）具有不同的采购行为、风险接受度和合约偏好，这些因素决定了商业合约结构和预期的技术转移。

区域能力、监管多样性和供应链走廊将决定疫苗製造投资将在何处提供战略弹性和商业性优势。

区域动态决定了在产能和能力方面的投资将在何处产生最大的策略回报。在美洲，快速取得先进的生技药品平台是当务之急，而透过同地技术团队和强大的分析能力来加速开发进度的伙伴关係往往更受青睐。该地区的监管事务强调与国际标准接轨，并通常支持优先项目的早期取得。

欧洲、中东和非洲呈现出多元化的监管和商业格局，灵活且区域分散的製造地备受青睐。这些地区的协调努力和跨境采购计画使策略合作更具吸引力，尤其是在政府和机构寻求增强韧性的情况下。亚太市场参与企业重视可扩展的平台、经济高效的生产以及日益成熟的合约开发和製造组织。从区域分析到行动，需要了解当地监管预期、劳动力可用性和物流走廊如何与技术选择和长期供应协议相互交织。

策略行动、能力投资和伙伴关係模式，使疫苗生产领域的高绩效契约製造製造商和服务供应商脱颖而出

疫苗受託製造领域公司之间的竞争动态取决于其在垂直整合、平台专业化和服务广度方面的策略投资。领先的开发商透过整合分析服务和开发专业知识来减少技术转移摩擦并加快临床开发时间，从而实现差异化。其他公司则专注于模组化产能和灵活的一次性生产，使其无需大规模改造即可应对更广泛的生产模式。联盟和策略伙伴关係，从产能共用协议到技术授权和合资模式，是缩小能力差距和加速进入新市场的常用机制。

在能力层面，那些在灌装-封口、强大的低温运输物流和检验的配方方法方面表现出稳定品质表现的公司，能够获得主要赞助商和公共采购商的优先合约。对数位化品质系统和资料完整性框架的投资已成为不可或缺的差异化因素，因为它们可以简化远端审核以及与监管机构的互动。从商业性角度来看，提供客製化合约条款（例如灵活的产能预留、基于里程碑的付款和风险共用模式）的组织更有可能赢得同样重视速度和可预测性的专案。因此，竞争格局不仅奖励技术卓越，也奖励商业性创造力和营运透明度。

为协调技术力、供应链弹性、承包模式和区域参与以加速疫苗计划的成功而提出的可行建议。

为了将洞察转化为竞争优势，产业领导者应专注于有针对性的可操作步骤，以降低专案风险并加速商业性进程。首先，优先考虑产能匹配，将疫苗模式和研发阶段与合作伙伴的专业知识相匹配。其次，透过对关键原材料和一次性组件的多家供应商进行资格审查，并制定包括区域采购和库存缓衝在内的紧急时应对计画，增强供应链的稳健性。

从营运角度来看，投资模组化设施设计和填充-封口自动化系统，可在不相应增加占地面积或人员的情况下提高产量。从商业性角度来看，建立兼顾灵活性和可预测性的合同，将产能预留与基于绩效的里程碑相结合。领导者还应投资分析和数位品质系统，以实现远端监控、更快的批次放行和更顺畅的监管提交。最后，在重点地区与当地相关人员建立选择性伙伴关係关係，以降低关税风险并加速市场准入。实施这些建议需要研发、供应链、品质和商业团队之间的跨职能协调，但这样做将显着提高专案的韧性和上市时间。

透明的混合方法研究设计，结合主要相关人员访谈、监管和技术证据以及交叉检验综合，为战略决策提供信息

这些见解背后的研究采用了混合方法，旨在对来自多个资料来源和相关人员观点的证据进行三角测量。主要数据是透过受託製造厂商的高层领导进行结构化访谈收集的，旨在了解营运现状和战略重点。二级资讯来源包括同行评审文献、监管指导文件、专利态势和公司技术揭露，以检验有关技术趋势和能力的主张。

透过交叉检验流程级证据和定性输入（例如标准作业程式、监管提交范本和技术转移案例研究）实现了分析的严谨性。资料品质保障措施包括访谈编码、方法和资料来源的透明度以及排除无法透过至少两个独立资讯来源证实的声明。这种方法强调可复製性和可追溯性，以便可以从原始输入到整合再到经营团队建议，追溯有关细分、区域动态和关税影响的结论。这种调查方法为决策者提供了采购、产能规划和伙伴关係选择的理由。

综合策略要务，展现综合能力设计、供应链弹性和伙伴关係关係如何影响计画和公共卫生成果。

技术创新、监管现代化和地缘政治压力的交汇，重新定义了疫苗契约製造的优先事项。成功的组织将能够将特定平台的卓越性与一体化服务产品、强大的供应链策略以及地域性投资选择相结合。本分析强调了将各种模式需求（从mRNA和病毒载体到基于蛋白质的平台）与合适的製造架构和分析能力相结合的重要性，同时还要考虑生物技术公司、政府机构和製药公司的采购实际情况。

总而言之，实现疫苗生产的弹性和高效，关键在于制定平衡的策略，以降低关税和供应链波动，利用灵活自动化的生产能力，并建立透明的商业伙伴关係关係。高阶主管应将製造外包视为一种战略能力，需要精心设计，而非单纯购买。透过采取有针对性的综合方法来选择合作伙伴并进行能力投资，组织可以降低专案风险，缩短开发时间，并提高向患者和公共卫生系统提供产品供应的可预测性。

目录

第一章 引言

第二章分析方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

• 疫情防治策略推动mRNA疫苗契约製造需求成长
• 扩大生技公司与CMO之间的合作关係，以扩大个人化癌症疫苗的生产管道
• 采用一次性生物反应器技术，提高疫苗生产的灵活性并降低交叉污染风险
• 协调监管工作，简化主要疫苗生产辖区的品质和合规要求
• 为解决全球管瓶和注射器短缺问题并加速疫苗分发，对灌装和封口能力的投资激增
• 整合数位双胞胎和即时分析，实现疫苗 CMO 设施的流程优化和预测性维护

第六章：美国关税的累积影响（2025年）

第七章：人工智慧（AI）的累积影响（2025年）

第八章疫苗契约製造市场（依疫苗类型）

• DNA
• 失活
• 活病毒疫苗
• mRNA
• 类毒素
• 病毒载体

9. 疫苗契约製造市场（依技术平台）

• 基于细胞
  • 贴壁细胞培养
  • 悬浮细胞培养
• 自拍
• 鸡蛋为主
• 合成胜肽

第 10 章疫苗契约製造市场（按服务提供）

• 分析服务
• 原料药(API) 製造
• 填充和整理
• 製造服务
• 分配
• 包装

第11章疫苗契约製造市场（依应用类型）

• 预防性疫苗
• 治疗性疫苗

第十二章疫苗契约製造市场（依使用阶段）

• 临床分期
  • 第一阶段
  • 第二阶段
  • 第三阶段
• 市场启动阶段

第十三章疫苗契约製造市场（按最终用户）

• 生技公司
• 政府机构
• 製药公司

第十四章疫苗契约製造市场（按地区）

• 美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第十五章疫苗契约製造市场（按类别）

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第十六章疫苗契约製造市场（依国家）

• 美国
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

第十七章竞争格局

• 2024年市占率分析
• 2024年FPNV定位矩阵
• 竞争分析
  • AbbVie Inc
  • Ajinomoto Co., Inc.
  • Aton（Shanghai）Biotech Co., Ltd.
  • Avid Bioservices, Inc.
  • Catalent, Inc.
  • Charles River Laboratories International, Inc.
  • CSL Limited
  • Curia Global, Inc.
  • Cytovance Biologics by Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
  • Emergent BioSolutions Inc.
  • FUJIFILM Diosynth Biotechnologies USA, Inc. by FUJIFILM Corporation
  • Gedeon Richter PLC
  • GlaxoSmithKline PLC
  • ICON PLC
  • IDT Biologika GmbH
  • KBI Biopharma, Inc. by JSR Corporation
  • Klocke Pharma-Service GmbH
  • Lonza Group Ltd.
  • Merck KGaA
  • Moderna, Inc.
  • Pfizer Inc.
  • Pharmaceutical Product Development by Thermo Fisher Scientific Inc.
  • Recipharm AB
  • Serum Institute of India
  • Vetter Pharma-Fertigung GmbH & Co. KG

The Vaccine Contract Manufacturing Market is projected to grow by USD 11.43 billion at a CAGR of 9.53% by 2032.

KEY MARKET STATISTICS
Base Year [2024]	USD 5.51 billion
Estimated Year [2025]	USD 6.04 billion
Forecast Year [2032]	USD 11.43 billion
CAGR (%)	9.53%

A strategic orientation that frames vaccine contract manufacturing as a critical capability shaping public health outcomes, commercialization speed, and cross-border resilience

The vaccine contract manufacturing landscape has evolved from a narrowly focused supply solution into a strategic axis of global public health, commercial drug development, and geopolitical resilience. Manufacturers, developers, and policy leaders are increasingly treating contract manufacturing as a configurable capability that shapes program timelines, regulatory risk, and patient access. As a result, decision-makers need an integrated perspective that connects technological competency with service orchestration across formulation, fill-finish, analytical characterization, and logistics.

This introduction sets the stage for that integrated perspective by highlighting how technological advances, regulatory expectations, and geopolitical pressures together create both risk and opportunity. It outlines the critical vectors that influence partner selection and capability investment: vaccine modality diversity, platform complexity, service scope, clinical and commercial stage requirements, and end-user priorities. By linking operational capabilities to strategic outcomes, the narrative that follows helps executive teams prioritize near-term actions-such as securing dual-source supply chains or accelerating validation of single-use systems-while keeping sight of longer-term imperatives like regional manufacturing capacity and workforce continuity. Transitioning from awareness to structured decision-making requires clarity about the interplay between science, regulation, and logistics; the content that follows offers that clarity in actionable terms.

How technological innovation, regulatory agility, and integrated service models are redefining competitive advantage in contract vaccine manufacturing

The past five years have produced transformative shifts that are changing how organizations source manufacturing and scientific services. Advances in mRNA and viral vector platforms, greater acceptance of modular and single-use facility architectures, and the emergence of cell-based and cell-free technologies have expanded the palette of feasible program designs. These technical shifts are accompanied by operational advances: more sophisticated analytics shorten development cycles, and automation in fill-finish reduces variability and accelerates scale-up timelines.

Concurrently, regulatory authorities have signaled a willingness to adopt more adaptive review pathways and rely on real-world data to support post-authorization monitoring. This regulatory evolution encourages sponsors and manufacturers to co-develop validation strategies that are field-ready and data-driven. Market participants are responding by forming deeper, capability-driven partnerships rather than one-off transactional contracts. As a result, contract manufacturers are moving upstream into drug substance work, formulation development, and integrated analytics to become full lifecycle partners. Taken together, these shifts create a new playing field where technological agility, regulatory savvy, and service integration determine competitive advantage and program resilience.

Assessment of how recent United States tariff dynamics are reshaping procurement strategies, supplier qualification, and regional investment decisions across vaccine manufacturing

Emerging trade policies and tariff scenarios in the United States introduced new cost and operational considerations that reverberate across global supply chains. Tariff-related frictions increase the total landed cost of imported raw materials, single-use components, and specialized instrumentation, prompting sponsors and manufacturers to reassess sourcing strategies. In response, organizations are diversifying supplier bases, qualifying regional substitutes for critical inputs, and accelerating inventory planning to protect program continuity.

The tariffs also influence location decisions for capital investments. Investors and strategic teams now weigh the resilience benefits of near-shore or on-shore capacity against the fixed cost advantages of established offshore capabilities. This calculus has prompted greater interest in establishing regional hubs that reduce exposure to cross-border trade policy volatility while preserving access to skilled labor pools and regulatory familiarity. In parallel, contract manufacturers are enhancing supply chain transparency and investing in procurement capabilities to mitigate tariff impacts. These operational responses reduce the likelihood of sudden program interruptions and enable sponsors to maintain timelines by adopting multi-modal logistics and local sourcing strategies where feasible.

Deep segmentation-driven insights that map vaccine modalities, platform architectures, service offerings, application stages, and end-user behaviors to partnership and investment choices

A nuanced segmentation lens clarifies where strategic value is concentrated and where capability gaps persist. When analyzing vaccine type diversity-spanning DNA, inactivated, live attenuated, mRNA, toxoid, and viral vector modalities-organizations must align technical requirements with manufacturing specialization, because each modality carries distinct upstream and downstream process needs and regulatory touchpoints. Technology platforms further stratify requirements: cell-based approaches are divided between adherent cell culture and suspension cell culture, while cell-free, egg-based, and synthetic peptide platforms introduce their own scale-up and analytical challenges.

Service offering segmentation reveals varying levels of integration and margin potential, with analytical services, drug substance manufacturing, fill-finish, formulation services, logistics, and packaging each demanding specific capabilities and quality systems. Application type differentiation into preventive and therapeutic vaccines influences batch release strategies, potency assays, and post-market surveillance approaches. Application stage is also material to partner selection: clinical-stage programs-spanning Phase I, Phase II, and Phase III studies-require flexible manufacturing and rapid change control, whereas commercial-stage programs demand validated capacity, sustained supply agreements, and mature quality management systems. Finally, end-user categories-biotech companies, government agencies, and pharmaceutical companies-bring differing procurement behaviors, risk tolerances, and contracting preferences, which in turn shape the structure of commercial contracts and technical transfer expectations.

Regional capacity, regulatory diversity, and supply chain corridors that determine where vaccine manufacturing investments yield strategic resilience and commercial advantage

Regional dynamics determine where investments in capacity and capability will deliver the greatest strategic returns. The Americas prioritize rapid access to advanced biologics platforms and tend to favor partnerships that compress development timelines through co-located technical teams and robust analytics. Regulatory pathways in the region emphasize alignment with international standards and often support accelerated access for priority programs, which in turn incentivizes local manufacturing and advanced fill-finish capabilities.

Europe, Middle East & Africa present a diverse regulatory and commercial tapestry that rewards flexible, regionally distributed manufacturing footprints. In these regions, harmonization efforts and cross-border procurement programs make strategic collaboration attractive, particularly when governments and agencies seek to build resilience. Asia-Pacific is characterized by a mix of high-capacity industrial infrastructure and emerging localized innovation hubs; market participants there emphasize scalable platforms, cost-efficient production, and increasingly sophisticated contract development and manufacturing organizations. Transitioning from regional analysis to action requires an appreciation for how local regulatory expectations, workforce availability, and logistics corridors intersect with technology selection and long-term supply agreements.

Strategic behaviors, capability investments, and partnership models that distinguish high-performing contract manufacturers and service providers in vaccine production

Competitive dynamics among companies operating in the contract vaccine manufacturing space are shaped by strategic investments in vertical integration, platform specialization, and service breadth. Leading organizations are differentiating by embedding analytical services and development expertise to reduce technical transfer friction and shorten time-to-clinic. Others emphasize modular capacity and flexible single-use manufacturing to serve a broader set of modalities without extensive retooling. Alliances and strategic partnerships-ranging from capacity-sharing agreements to technology licensing and joint venture models-are common mechanisms for closing capability gaps and accelerating access to new geographies.

At the capability level, firms that demonstrate consistent quality performance in fill-finish, robust cold chain logistics, and validated formulation approaches secure preferential contracting with large sponsors and public purchasers. Investment in digital quality systems and data integrity frameworks has become a non-negotiable differentiator, enabling remote audits and streamlined regulatory interactions. From a commercial posture, organizations offering tailored contracting terms-such as flexible capacity reservation, milestone-based payments, and shared-risk models-tend to win programs where speed and predictability are equally valued. The competitive landscape thus rewards not only technical excellence but also commercial creativity and operational transparency.

Actionable recommendations for aligning technical capability, supply chain resilience, contracting models, and regional engagement to accelerate vaccine program success

To translate insight into competitive advantage, industry leaders should focus on targeted, actionable steps that reduce program risk and accelerate commercial progress. First, prioritize capability alignment by matching vaccine modality and development stage with partner specialization; this reduces technical transfer time and minimizes rework during scale-up. Next, strengthen supply chain robustness by qualifying multiple suppliers for critical raw materials and single-use components, and by developing contingency plans that include regional sourcing and inventory buffers.

Operationally, invest in modular facility designs and automation in fill-finish to increase throughput without proportionate increases in footprint or headcount. From a commercial perspective, structure contracts that balance flexibility and predictability-combining capacity reservations with performance-based milestones. Leaders should also invest in analytics and digital quality systems to enable remote oversight, faster batch release, and smoother regulatory submissions. Finally, pursue selective partnerships with local stakeholders in priority regions to reduce tariff exposure and accelerate market entry. Implementing these recommendations will require cross-functional coordination between R&D, supply chain, quality, and commercial teams, but doing so yields measurable improvements in program resilience and time-to-market.

Transparent mixed-methods research design combining primary stakeholder interviews, regulatory and technical evidence, and cross-validated synthesis to inform strategic decisions

The research underpinning these insights uses a mixed-methods approach designed to triangulate evidence from multiple data sources and stakeholder perspectives. Primary data were collected through structured interviews with senior leaders across contract manufacturing organizations, vaccine developers, regulatory advisors, and procurement authorities to capture operational realities and strategic priorities. Secondary sources included peer-reviewed literature, regulatory guidance documents, patent landscapes, and company technical disclosures to validate technological trends and capability claims.

Analytical rigor was achieved through cross-validation of qualitative inputs with process-level evidence, such as standard operating procedures, regulatory filing templates, and technology transfer case studies. Data quality safeguards included interview coding, methodological transparency, and the exclusion of claims that could not be corroborated with at least two independent sources. The approach emphasizes reproducibility and traceability so that conclusions about segmentation, regional dynamics, and tariff impacts can be followed from raw inputs through synthesis to executive recommendations. This methodology provides decision-makers with a defensible basis for procurement, capacity planning, and partnership selection.

Synthesis of strategic imperatives demonstrating how integrated capability design, supply chain resilience, and partnership alignment determine program and public health outcomes

The converging forces of technological innovation, regulatory modernization, and geopolitical pressure have redefined the priorities for vaccine contract manufacturing. Organizations that succeed will be those that combine platform-specific technical excellence with integrated service offerings, robust supply chain strategies, and regionally informed investment choices. The analysis highlights the importance of aligning modality requirements-from mRNA and viral vectors to protein-based platforms-with the appropriate manufacturing architectures and analytics capabilities, while also accounting for the realities of procurement behavior across biotech firms, government bodies, and pharmaceutical companies.

In sum, the path to resilient and efficient vaccine manufacturing lies in a balanced strategy that mitigates tariff and supply chain volatility, leverages flexible and automated production capacity, and cultivates transparent commercial partnerships. Executives should view contract manufacturing as a strategic capability to be designed, not merely purchased. By taking a deliberate, integrated approach to partner selection and capability investment, organizations can reduce program risk, compress development timelines, and improve the predictability of product supply to patients and public health systems.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Growing demand for mRNA vaccine contract manufacturing capacity accelerated by pandemic preparedness strategies
• 5.2. Increasing partnerships between biotech firms and CMOs to scale up personalized cancer vaccine production pipelines
• 5.3. Adoption of single-use bioreactor technologies to enhance flexibility and reduce cross-contamination risks in vaccine manufacturing
• 5.4. Regulatory harmonization efforts streamlining quality and compliance requirements across major vaccine production jurisdictions
• 5.5. Investment surge in fill-finish capabilities to address global shortages of vials and syringes and expedite vaccine distribution
• 5.6. Integration of digital twins and real-time analytics for process optimization and predictive maintenance in vaccine CMO facilities

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Vaccine Contract Manufacturing Market, by Vaccine Type

• 8.1. DNA
• 8.2. Inactivated
• 8.3. Live Attenuated
• 8.4. MRNA
• 8.5. Toxoid
• 8.6. Viral Vector

9. Vaccine Contract Manufacturing Market, by Technology Platform

• 9.1. Cell Based
  • 9.1.1. Adherent Cell Culture
  • 9.1.2. Suspension Cell Culture
• 9.2. Cell Free
• 9.3. Egg Based
• 9.4. Synthetic Peptide

10. Vaccine Contract Manufacturing Market, by Service Offering

• 10.1. Analytical Services
• 10.2. Drug Substance Manufacturing
• 10.3. Fill Finish
• 10.4. Formulation Services
• 10.5. Logistics
• 10.6. Packaging

11. Vaccine Contract Manufacturing Market, by Application Type

• 11.1. Preventive Vaccines
• 11.2. Therapeutic Vaccines

12. Vaccine Contract Manufacturing Market, by Application Stage

• 12.1. Clinical Stage
  • 12.1.1. Phase I
  • 12.1.2. Phase Ii
  • 12.1.3. Phase Iii
• 12.2. Commercial Stage

13. Vaccine Contract Manufacturing Market, by End User

• 13.1. Biotech Companies
• 13.2. Government Agencies
• 13.3. Pharmaceutical Companies

14. Vaccine Contract Manufacturing Market, by Region

• 14.1. Americas
  • 14.1.1. North America
  • 14.1.2. Latin America
• 14.2. Europe, Middle East & Africa
  • 14.2.1. Europe
  • 14.2.2. Middle East
  • 14.2.3. Africa
• 14.3. Asia-Pacific

15. Vaccine Contract Manufacturing Market, by Group

• 15.1. ASEAN
• 15.2. GCC
• 15.3. European Union
• 15.4. BRICS
• 15.5. G7
• 15.6. NATO

16. Vaccine Contract Manufacturing Market, by Country

• 16.1. United States
• 16.2. Canada
• 16.3. Mexico
• 16.4. Brazil
• 16.5. United Kingdom
• 16.6. Germany
• 16.7. France
• 16.8. Russia
• 16.9. Italy
• 16.10. Spain
• 16.11. China
• 16.12. India
• 16.13. Japan
• 16.14. Australia
• 16.15. South Korea

17. Competitive Landscape

• 17.1. Market Share Analysis, 2024
• 17.2. FPNV Positioning Matrix, 2024
• 17.3. Competitive Analysis
  • 17.3.1. AbbVie Inc
  • 17.3.2. Ajinomoto Co., Inc.
  • 17.3.3. Aton (Shanghai) Biotech Co., Ltd.
  • 17.3.4. Avid Bioservices, Inc.
  • 17.3.5. Catalent, Inc.
  • 17.3.6. Charles River Laboratories International, Inc.
  • 17.3.7. CSL Limited
  • 17.3.8. Curia Global, Inc.
  • 17.3.9. Cytovance Biologics by Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
  • 17.3.10. Emergent BioSolutions Inc.
  • 17.3.11. FUJIFILM Diosynth Biotechnologies U.S.A., Inc. by FUJIFILM Corporation
  • 17.3.12. Gedeon Richter PLC
  • 17.3.13. GlaxoSmithKline PLC
  • 17.3.14. ICON PLC
  • 17.3.15. IDT Biologika GmbH
  • 17.3.16. KBI Biopharma, Inc. by JSR Corporation
  • 17.3.17. Klocke Pharma-Service GmbH
  • 17.3.18. Lonza Group Ltd.
  • 17.3.19. Merck KGaA
  • 17.3.20. Moderna, Inc.
  • 17.3.21. Pfizer Inc.
  • 17.3.22. Pharmaceutical Product Development by Thermo Fisher Scientific Inc.
  • 17.3.23. Recipharm AB
  • 17.3.24. Serum Institute of India
  • 17.3.25. Vetter Pharma-Fertigung GmbH & Co. KG

LIST OF FIGURES

• FIGURE 1. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2024 VS 2032 (%)
• FIGURE 3. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 4. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2024 VS 2032 (%)
• FIGURE 5. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2024 VS 2032 (%)
• FIGURE 7. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2024 VS 2032 (%)
• FIGURE 9. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2024 VS 2032 (%)
• FIGURE 11. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 12. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
• FIGURE 13. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 14. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 15. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 16. NORTH AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 17. LATIN AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 19. EUROPE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 20. MIDDLE EAST VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 21. AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 22. ASIA-PACIFIC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 23. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 24. ASEAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 25. GCC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 26. EUROPEAN UNION VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 27. BRICS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 28. G7 VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 29. NATO VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 30. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 31. VACCINE CONTRACT MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 32. VACCINE CONTRACT MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. VACCINE CONTRACT MANUFACTURING MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, 2025-2032 (USD MILLION)
• TABLE 5. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
• TABLE 7. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DNA, BY REGION, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DNA, BY REGION, 2025-2032 (USD MILLION)
• TABLE 9. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DNA, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DNA, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 11. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DNA, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DNA, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 13. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY INACTIVATED, BY REGION, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY INACTIVATED, BY REGION, 2025-2032 (USD MILLION)
• TABLE 15. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY INACTIVATED, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY INACTIVATED, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 17. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY INACTIVATED, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY INACTIVATED, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 19. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2025-2032 (USD MILLION)
• TABLE 21. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY LIVE ATTENUATED, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY LIVE ATTENUATED, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 23. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY LIVE ATTENUATED, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY LIVE ATTENUATED, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 25. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY MRNA, BY REGION, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY MRNA, BY REGION, 2025-2032 (USD MILLION)
• TABLE 27. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY MRNA, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY MRNA, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 29. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY MRNA, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY MRNA, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 31. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TOXOID, BY REGION, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TOXOID, BY REGION, 2025-2032 (USD MILLION)
• TABLE 33. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TOXOID, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TOXOID, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 35. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TOXOID, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TOXOID, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 37. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2025-2032 (USD MILLION)
• TABLE 39. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 41. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 43. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
• TABLE 45. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2025-2032 (USD MILLION)
• TABLE 47. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, BY REGION, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, BY REGION, 2025-2032 (USD MILLION)
• TABLE 49. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 51. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 53. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY ADHERENT CELL CULTURE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY ADHERENT CELL CULTURE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 55. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY ADHERENT CELL CULTURE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY ADHERENT CELL CULTURE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 57. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY ADHERENT CELL CULTURE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY ADHERENT CELL CULTURE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 59. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SUSPENSION CELL CULTURE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SUSPENSION CELL CULTURE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 61. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SUSPENSION CELL CULTURE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SUSPENSION CELL CULTURE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 63. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SUSPENSION CELL CULTURE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SUSPENSION CELL CULTURE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 65. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL FREE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL FREE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 67. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL FREE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL FREE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 69. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL FREE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL FREE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 71. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY EGG BASED, BY REGION, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY EGG BASED, BY REGION, 2025-2032 (USD MILLION)
• TABLE 73. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY EGG BASED, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY EGG BASED, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 75. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY EGG BASED, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY EGG BASED, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 77. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SYNTHETIC PEPTIDE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SYNTHETIC PEPTIDE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 79. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SYNTHETIC PEPTIDE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SYNTHETIC PEPTIDE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 81. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SYNTHETIC PEPTIDE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SYNTHETIC PEPTIDE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 83. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2025-2032 (USD MILLION)
• TABLE 85. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL SERVICES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL SERVICES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 87. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL SERVICES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL SERVICES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 89. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 91. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DRUG SUBSTANCE MANUFACTURING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DRUG SUBSTANCE MANUFACTURING, BY REGION, 2025-2032 (USD MILLION)
• TABLE 93. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DRUG SUBSTANCE MANUFACTURING, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 94. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DRUG SUBSTANCE MANUFACTURING, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 95. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DRUG SUBSTANCE MANUFACTURING, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 96. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DRUG SUBSTANCE MANUFACTURING, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 97. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FILL FINISH, BY REGION, 2018-2024 (USD MILLION)
• TABLE 98. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FILL FINISH, BY REGION, 2025-2032 (USD MILLION)
• TABLE 99. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FILL FINISH, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 100. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FILL FINISH, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 101. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FILL FINISH, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 102. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FILL FINISH, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 103. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FORMULATION SERVICES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 104. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FORMULATION SERVICES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 105. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FORMULATION SERVICES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 106. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FORMULATION SERVICES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 107. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FORMULATION SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 108. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FORMULATION SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 109. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY LOGISTICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 110. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY LOGISTICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 111. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY LOGISTICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 112. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY LOGISTICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 113. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY LOGISTICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 114. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY LOGISTICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 115. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 116. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING, BY REGION, 2025-2032 (USD MILLION)
• TABLE 117. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 118. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 119. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 120. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 121. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2018-2024 (USD MILLION)
• TABLE 122. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2025-2032 (USD MILLION)
• TABLE 123. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PREVENTIVE VACCINES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 124. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PREVENTIVE VACCINES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 125. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PREVENTIVE VACCINES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 126. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PREVENTIVE VACCINES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 127. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PREVENTIVE VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 128. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PREVENTIVE VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 129. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC VACCINES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 130. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC VACCINES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 131. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC VACCINES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 132. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC VACCINES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 133. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 134. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 135. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2018-2024 (USD MILLION)
• TABLE 136. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2025-2032 (USD MILLION)
• TABLE 137. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2018-2024 (USD MILLION)
• TABLE 138. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2025-2032 (USD MILLION)
• TABLE 139. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 140. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 141. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 142. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 143. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 144. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 145. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PHASE I, BY REGION, 2018-2024 (USD MILLION)
• TABLE 146. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PHASE I, BY REGION, 2025-2032 (USD MILLION)
• TABLE 147. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PHASE I, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 148. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PHASE I, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 149. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PHASE I, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 150. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PHASE I, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 151. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PHASE II, BY REGION, 2018-2024 (USD MILLION)
• TABLE 152. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PHASE II, BY REGION, 2025-2032 (USD MILLION)
• TABLE 153. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PHASE II, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 154. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PHASE II, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 155. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PHASE II, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 156. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PHASE II, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 157. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PHASE III, BY REGION, 2018-2024 (USD MILLION)
• TABLE 158. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PHASE III, BY REGION, 2025-2032 (USD MILLION)
• TABLE 159. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PHASE III, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 160. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PHASE III, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 161. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PHASE III, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 162. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PHASE III, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 163. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COMMERCIAL STAGE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 164. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COMMERCIAL STAGE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 165. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COMMERCIAL STAGE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 166. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COMMERCIAL STAGE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 167. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COMMERCIAL STAGE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 168. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COMMERCIAL STAGE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 169. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 170. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 171. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY BIOTECH COMPANIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 172. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY BIOTECH COMPANIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 173. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY BIOTECH COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 174. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY BIOTECH COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 175. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY BIOTECH COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 176. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY BIOTECH COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 177. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY GOVERNMENT AGENCIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 178. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY GOVERNMENT AGENCIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 179. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY GOVERNMENT AGENCIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 180. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY GOVERNMENT AGENCIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 181. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY GOVERNMENT AGENCIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 182. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY GOVERNMENT AGENCIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 183. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 184. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 185. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 186. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 187. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 188. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 189. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 190. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 191. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 192. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 193. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
• TABLE 194. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
• TABLE 195. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
• TABLE 196. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
• TABLE 197. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2018-2024 (USD MILLION)
• TABLE 198. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2025-2032 (USD MILLION)
• TABLE 199. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2018-2024 (USD MILLION)
• TABLE 200. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2025-2032 (USD MILLION)
• TABLE 201. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2018-2024 (USD MILLION)
• TABLE 202. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2025-2032 (USD MILLION)
• TABLE 203. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2018-2024 (USD MILLION)
• TABLE 204. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2025-2032 (USD MILLION)
• TABLE 205. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2018-2024 (USD MILLION)
• TABLE 206. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2025-2032 (USD MILLION)
• TABLE 207. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 208. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 209. NORTH AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 210. NORTH AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 211. NORTH AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
• TABLE 212. NORTH AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
• TABLE 213. NORTH AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
• TABLE 214. NORTH AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
• TABLE 215. NORTH AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2018-2024 (USD MILLION)
• TABLE 216. NORTH AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2025-2032 (USD MILLION)
• TABLE 217. NORTH AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2018-2024 (USD MILLION)
• TABLE 218. NORTH AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2025-2032 (USD MILLION)
• TABLE 219. NORTH AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2018-2024 (USD MILLION)
• TABLE 220. NORTH AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2025-2032 (USD MILLION)
• TABLE 221. NORTH AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2018-2024 (USD MILLION)
• TABLE 222. NORTH AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2025-2032 (USD MILLION)
• TABLE 223. NORTH AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2018-2024 (USD MILLION)
• TABLE 224. NORTH AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2025-2032 (USD MILLION)
• TABLE 225. NORTH AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 226. NORTH AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 227. LATIN AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 228. LATIN AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 229. LATIN AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
• TABLE 230. LATIN AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
• TABLE 231. LATIN AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
• TABLE 232. LATIN AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
• TABLE 233. LATIN AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2018-2024 (USD MILLION)
• TABLE 234. LATIN AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2025-2032 (USD MILLION)
• TABLE 235. LATIN AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2018-2024 (USD MILLION)
• TABLE 236. LATIN AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2025-2032 (USD MILLION)
• TABLE 237. LATIN AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2018-2024 (USD MILLION)
• TABLE 238. LATIN AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2025-2032 (USD MILLION)
• TABLE 239. LATIN AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2018-2024 (USD MILLION)
• TABLE 240. LATIN AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2025-2032 (USD MILLION)
• TABLE 241. LATIN AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2018-2024 (USD MILLION)
• TABLE 242. LATIN AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2025-2032 (USD MILLION)
• TABLE 243. LATIN AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 244. LATIN AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 245. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 246. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 247. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
• TABLE 248. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
• TABLE 249. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
• TABLE 250. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
• TABLE 251. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2018-2024 (USD MILLION)
• TABLE 252. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2025-2032 (USD MILLION)
• TABLE 253. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2018-2024 (USD MILLION)
• TABLE 254. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2025-2032 (USD MILLION)
• TABLE 255. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2018-2024 (USD MILLION)
• TABLE 256. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2025-2032 (USD MILLION)
• TABLE 257. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2018-2024 (USD MILLION)
• TABLE 258. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2025-2032 (USD MILLION)
• TABLE 259. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2018-2024 (USD MILLION)
• TABLE 260. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2025-2032 (USD MILLION)
• TABLE 261. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 262. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 263. EUROPE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 264. EUROPE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 265. EUROPE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
• TABLE 266. EUROPE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
• TABLE 267. EUROPE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
• TABLE 268. EUROPE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
• TABLE 269. EUROPE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2018-2024 (USD MILLION)
• TABLE 270. EUROPE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2025-2032 (USD MILLION)
• TABLE 271. EUROPE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2018-2024 (USD MILLION)
• TABLE 272. EUROPE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2025-2032 (USD MILLION)
• TABLE 273. EUROPE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2018-2024 (USD MILLION)
• TABLE 274. EUROPE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2025-2032 (USD MILLION)
• TABLE 275. EUROPE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2018-2024 (USD MILLION)
• TABLE 276. EUROPE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2025-2032 (USD MILLION)
• TABLE 277. EUROPE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2018-2024 (USD MILLION)
• TABLE 278. EUROPE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2025-2032 (USD MILLION)
• TABLE 279. EUROPE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 280. EUROPE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 281. MIDDLE EAST VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 282. MIDDLE EAST VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 283. MIDDLE EAST VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
• TABLE 284. MIDDLE EAST VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
• TABLE 285. MIDDLE EAST VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
• TABLE 286. MIDDLE EAST VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
• TABLE 287. MIDDLE EAST VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2018-2024 (USD MILLION)
• TABLE 288. MIDDLE EAST VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2025-2032 (USD MILLION)
• TABLE 289. MIDDLE EAST VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2018-2024 (USD MILLION)
• TABLE 290. MIDDLE EAST VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2025-2032 (USD MILLION)
• TABLE 291. MIDDLE EAST VACCINE CONTRACT MANUFACTURING MARKET SIZE,